Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. heart stroke
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Videos

Refine by
Date

  • Older

Heart Stroke Articles & Analysis

71 news found

Creative Enzymes Unveils Semaglutide, a Promising Solution for Comprehensive Diabetes Management

Creative Enzymes Unveils Semaglutide, a Promising Solution for Comprehensive Diabetes Management

Furthermore, Semaglutide has demonstrated the ability to reduce the risk of cardiovascular events, such as heart attacks and strokes, in individuals with type 2 diabetes and established cardiovascular disease. ...

ByCreative Enzymes


Understanding the Connection between Hay Fever and Snoring

Understanding the Connection between Hay Fever and Snoring

As we move towards the New Year, we’ll be anxiously awaiting the warming days of springtime. Well, most of us will anyway. Fortunately for many of us, and unfortunately for many others, it means flowers will be in bloom after spring rains and some of us will be suffering with seasonal allergic rhinitis, more commonly referred to as hay fever. It’s all about the coughing, the red ...

ByTannerMedico A/S - Asonor


CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation

CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation

Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments, over heart attacks and strokes, to age-related degeneration. "Whilst Mitochondria have been known as disease targets for a long time, treating them has proven challenging", notes Dr. ...

Bycellvie Inc.


Revacept protects during carotid artery surgery

Revacept protects during carotid artery surgery

Good news from vascular medicine: the innovative drug Revacept can protect people with narrowed carotid arteries from both further strokes and dangerous bleeding. Thanks to this completely new dual efficacy, Revacept is ideal for preventing complications after stroke prevention surgery on narrowed carotid arteries. ...

ByadvanceCOR GmbH


World Diabetes Day

World Diabetes Day

If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye disease, kidney disease and nerve damage. ...

ByNeurovalens Limited


Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer. ...

ByGalapagos NV


Elucid’s Next-Generation Plaque Analysis and FFRCT Technology to be Featured on 2022 AHA Scientific Sessions Program

Elucid’s Next-Generation Plaque Analysis and FFRCT Technology to be Featured on 2022 AHA Scientific Sessions Program

“This highly accurate plaque analysis is the foundation for our next-generation CT-derived fractional flow reserve analysis and provides patients and providers with a personalized measure of risk so that their treatment can be tailored to prevent cardiac events like heart attack and stroke.” Program sessions featuring Elucid’s technology ...

ByElucid


Elucid Appoints Dr. Michael Lesh to Board of Directors

Elucid Appoints Dr. Michael Lesh to Board of Directors

Advanced clinical insights from Elucid equip physicians with critical information designed to enable precision medicine for both assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke, as well as assessing blockages to determine the need for revascularization. ...

ByElucid


Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Strokes can be classified into two major categories: haemorrhagic stroke and ischemic stroke. 85% of all strokes are ischemic strokes, caused by an interruption of blood supply to the brain due to a blockage e.g., a blood clot. ...

ByBayer AG


Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer

Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer

“I am convinced that Elucid’s pioneering computed tomography-based technology will fundamentally shift how we treat and prevent heart disease. The company’s technology helps physicians fl ag the patients who are truly at risk for heart attacks and stroke and directs a patient-specific treatment pathway. ...

ByElucid


Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch Ventricular Restoration System

Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch Ventricular Restoration System

– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. ...

ByAncora Heart, Inc


£1.1 million project to develop new biodegradable stents

£1.1 million project to develop new biodegradable stents

Severe peripheral vascular disease (PVD) is caused by the formation of blockages in arteries, which reduces blood supply to the brain, heart, kidneys and limbs causing strokes, heart attacks, kidney failure and limb amputations. ...

ByArterius Limited


Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

Specifically, the exquisite algorithms developed through machine learning characterize tissue types in the artery wall known to cause heart attacks, such as lipid rich necrotic core. The capability to discern complex plaque biology at the cellular and molecular level is powering new applications that can derive fractional flow reserve (FFRct), risk of heart ...

ByElucid


Rivaroxaban (Xarelto) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation

Rivaroxaban (Xarelto) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation

The primary efficacy endpoint was a composite of MALE and MACE, ie. acute limb ischemia, major amputation of a vascular etiology, heart attack (myocardial infarction, MI), ischemic stroke or cardiovascular death. ...

ByBayer AG


Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz Immunotherapy Platform

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz Immunotherapy Platform

In combination with work continuing at the University of Miami, we believe that our ImmCelz® platform has enormous potential to improve outcomes for patients across multiple indications, including Stroke, Type I Diabetes, Heart Disease, Liver Disease, and Kidney Disease." ...

ByCreative Medical Technology Holdings, Inc. (CELZ)


Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference

Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference

High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in people with ...

ByVertex Pharmaceuticals


Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes

Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes

High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in people with ...

ByVertex Pharmaceuticals


Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company`s ImmCelz Product

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company`s ImmCelz Product

We believe that our Immcelz® program has enormous potential to improve outcomes for patients across multiple indications, including stroke, Type I diabetes, heart disease, liver disease, and kidney disease." ...

ByCreative Medical Technology Holdings, Inc. (CELZ)


Alfa Chemistry Optimizes Supply of Glycerides: Monoglycerides, Diglycerides, Triglycerides

Alfa Chemistry Optimizes Supply of Glycerides: Monoglycerides, Diglycerides, Triglycerides

High levels of triglycerides in the bloodstream have been linked to atherosclerosis, heart disease and stroke. Monoglycerides and diglycerides are called partial glycerides. ...

ByAlfa Chemistry


Signifier Medical Technologies Announces $49MM Purchase of Existing Shares by Waha Capital, Angelus Sano Ventures and Segulah Medical Acceleration

Signifier Medical Technologies Announces $49MM Purchase of Existing Shares by Waha Capital, Angelus Sano Ventures and Segulah Medical Acceleration

Nearly one billion adults aged 30 to 69 years globally are estimated to suffer from OSA (Obstructive Sleep Apnea), which is a serious medical condition associated with health problems such as high blood pressure and increased risks of heart attack, stroke or death.1-10 Waha Capital is an Abu Dhabi listed investment management company and is one of the United ...

BySignifier Medical Technologies Ltd

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT